Generalized Myasthenia Gravis Clinical Trial
Official title:
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel, Multicenter Study to Evaluate the Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis
The purpose of this study is to evaluate the safety and efficacy of ALXN1720 for the treatment of generalized MG (gMG) in adults with autoantibodies against acetylcholine receptor (AChR).
| Status | Recruiting |
| Enrollment | 254 |
| Est. completion date | July 7, 2027 |
| Est. primary completion date | August 5, 2025 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: - Diagnosis of MG with generalized muscle weakness meeting the clinical criteria defined by Myasthenia Gravis Foundation of America (MGFA) Class II, III or IV - Positive serological test for autoantibodies against AChR Exclusion Criteria: - History of thymectomy, or any other thymic surgery within 12 months prior to Screening - Untreated thymic malignancy, carcinoma, or thymoma - History of Neisseria meningitidis infection - Pregnancy, breastfeeding, or intention to conceive during the course of the study |
| Country | Name | City | State |
|---|---|---|---|
| Argentina | Research Site | Buenos Aires | |
| Argentina | Research Site | Buenos Aires | |
| Argentina | Research Site | Caba | |
| Argentina | Research Site | Caba | |
| Argentina | Research Site | Capital Federal | |
| Argentina | Research Site | Rosario | |
| Austria | Research Site | Innsbruck | |
| Austria | Research Site | Vienna | |
| Austria | Research Site | Wels-Grieskirchen | |
| Brazil | Research Site | Barretos | |
| Brazil | Research Site | Joinville | |
| Brazil | Research Site | Porto Alegre | |
| Brazil | Research Site | Ribeirão Preto | |
| Brazil | Research Site | Salvador | |
| Brazil | Research Site | Sao Jose Do Rio Preto | |
| Brazil | Research Site | Sao Paulo | |
| Brazil | Research Site | São Paulo | |
| Canada | Research Site | Edmonton | Alberta |
| Canada | Research Site | London | Ontario |
| Canada | Research Site | Montreal | Quebec |
| Canada | Research Site | Quebec City | Quebec |
| Canada | Research Site | Toronto | Ontario |
| China | Research Site | Beijing | |
| China | Research Site | Beijing | |
| China | Research Site | Changchun | |
| China | Research Site | Changsha | |
| China | Research Site | Chengdu | |
| China | Research Site | Chongqing | |
| China | Research Site | Fuzhou | |
| China | Research Site | Hangzhou | |
| China | Research Site | Hangzhou | |
| China | Research Site | Jinan | |
| China | Research Site | Qingdao | |
| China | Research Site | Shanghai | |
| China | Research Site | Suzhou | |
| China | Research Site | Wuhan | |
| China | Research Site | Xi'an | |
| Denmark | Research Site | Aalborg | |
| Denmark | Research Site | København Ø | |
| France | Research Site | Angers | |
| France | Research Site | Garches | |
| France | Research Site | Lille | |
| France | Research Site | Marseille | |
| France | Research Site | Montpellier Cedex 5 | |
| France | Research Site | Nice | |
| France | Research Site | Paris Cedex 13 | |
| France | Research Site | Strasbourg Cedex | |
| Germany | Research Site | Berlin | |
| Germany | Research Site | Düsseldorf | |
| Germany | Research Site | Giessen | |
| Germany | Research Site | München | |
| Germany | Research Site | München | |
| Germany | Research Site | Tübingen | |
| Germany | Research Site | Wuerzburg | |
| Israel | Research Site | Hadera | |
| Israel | Research Site | Haifa | |
| Israel | Research Site | Petah Tikva | |
| Israel | Research Site | Ramat Gan | |
| Italy | Research Site | Bergamo | |
| Italy | Research Site | Brescia | |
| Italy | Research Site | Firenze | |
| Italy | Research Site | Milano | |
| Italy | Research Site | Napoli | |
| Italy | Research Site | Palermo | |
| Italy | Research Site | Roma | |
| Italy | Research Site | Rome | |
| Italy | Research Site | Treviso | |
| Italy | Research Site | Udine | |
| Japan | Research Site | Chiba-shi | |
| Japan | Research Site | Fukushima-shi | |
| Japan | Research Site | Higashimatsuyama | |
| Japan | Research Site | Hiroshima-shi | |
| Japan | Research Site | Isehara-shi | |
| Japan | Research Site | Itabashi-ku | |
| Japan | Research Site | Kawasaki-shi | |
| Japan | Research Site | Morioka | |
| Japan | Research Site | Nagasaki | |
| Japan | Research Site | Nagoya | |
| Japan | Research Site | Nagoya-shi | |
| Japan | Research Site | Ota-ku | |
| Japan | Research Site | Shinjuku-ku | |
| Japan | Research Site | Shinjuku-ku | |
| Japan | Research Site | Shinjuku-ku | |
| Japan | Research Site | Suita-shi | |
| Korea, Republic of | Research Site | Busan | |
| Korea, Republic of | Research Site | Daegu | |
| Korea, Republic of | Research Site | Gwangju | |
| Korea, Republic of | Research Site | Seoul | |
| Korea, Republic of | Research Site | Seoul | |
| Korea, Republic of | Research Site | Seoul | |
| Korea, Republic of | Research Site | Seoul | |
| Korea, Republic of | Research Site | Seoul | |
| Netherlands | Research Site | Amsterdam | |
| Poland | Research Site | Bydgoszcz | |
| Poland | Research Site | Katowice | |
| Poland | Research Site | Kraków | |
| Poland | Research Site | Kraków | |
| Poland | Research Site | Lublin | |
| Poland | Research Site | Poznan | |
| Portugal | Research Site | Almada | |
| Portugal | Research Site | Porto | |
| Serbia | Research Site | Belgrade | |
| Serbia | Research Site | Nis | |
| Spain | Research Site | Badalona(Barcelona) | |
| Spain | Research Site | Córdoba | |
| Spain | Research Site | Hospitalet de Llobregat | |
| Spain | Research Site | Madrid | |
| Spain | Research Site | Madrid | |
| Spain | Research Site | Madrid | |
| Spain | Research Site | Málaga | |
| Spain | Research Site | Pamplona | |
| Spain | Research Site | San Sebastián de los Reyes | |
| Spain | Research Site | Sevilla | |
| Switzerland | Research Site | Lugano | |
| Switzerland | Research Site | St. Gallen | |
| Switzerland | Research Site | Zürich | |
| Taiwan | Research Site | Kaohsiung City | |
| Taiwan | Research Site | Tainan City | |
| Taiwan | Research Site | Taipei | |
| Taiwan | Research Site | Taipei | |
| Turkey | Research Site | Atakum | |
| Turkey | Research Site | Bursa | |
| Turkey | Research Site | Istanbul | |
| Turkey | Research Site | Kocaeli | |
| Turkey | Research Site | Kütahya | |
| United Kingdom | Research Site | Liverpool | |
| United Kingdom | Research Site | London | |
| United Kingdom | Research Site | Oxford | |
| United Kingdom | Research Site | Sheffield | |
| United States | Research Site | Augusta | Georgia |
| United States | Research Site | Aurora | Colorado |
| United States | Research Site | Boston | Massachusetts |
| United States | Research Site | Bradenton | Florida |
| United States | Research Site | Brighton | Massachusetts |
| United States | Research Site | Chapel Hill | North Carolina |
| United States | Research Site | Detroit | Michigan |
| United States | Research Site | Durham | North Carolina |
| United States | Research Site | East Lansing | Michigan |
| United States | Research Site | Fort Collins | Colorado |
| United States | Research Site | Gainesville | Georgia |
| United States | Research Site | Kansas City | Kansas |
| United States | Research Site | Las Vegas | Nevada |
| United States | Research Site | Lexington | Kentucky |
| United States | Research Site | Los Angeles | California |
| United States | Research Site | Madison | Wisconsin |
| United States | Research Site | Maitland | Florida |
| United States | Research Site | McAllen | Texas |
| United States | Research Site | Morgantown | West Virginia |
| United States | Research Site | North Charleston | South Carolina |
| United States | Research Site | Orange | California |
| United States | Research Site | Orlando | Florida |
| United States | Research Site | Patchogue | New York |
| United States | Research Site | Phoenix | Arizona |
| United States | Research Site | Portland | Oregon |
| United States | Research Site | Rancho Mirage | California |
| United States | Research Site | Richmond | Virginia |
| United States | Research Site | Rochester | New York |
| United States | Research Site | Savannah | Georgia |
| United States | Research Site | Seattle | Washington |
| United States | Research Site | Springfield | Illinois |
| United States | Research Site | Syracuse | New York |
| United States | Research Site | Tampa | Florida |
| United States | Research Site | Washington | District of Columbia |
| Lead Sponsor | Collaborator |
|---|---|
| Alexion Pharmaceuticals, Inc. |
United States, Argentina, Austria, Brazil, Canada, China, Denmark, France, Germany, Israel, Italy, Japan, Korea, Republic of, Netherlands, Poland, Portugal, Serbia, Spain, Switzerland, Taiwan, Turkey, United Kingdom,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Change From Baseline in Myasthenia Gravis-Activities of Daily Living (MG-ADL) Total Score at Week 26 | Baseline, Week 26 | ||
| Secondary | Change From Baseline in Quantitative Myasthenia Gravis (QMG) Total Score at Week 26 | Baseline, Week 26 | ||
| Secondary | Percentage of Responders Based on Reduction of the MG-ADL Total Score at Week 26 | Response is defined as reduction of the MG-ADL total score by >= 3 points from baseline at Week 26. | Baseline up to Week 26 | |
| Secondary | Percentage of Responders based on Reduction of the QMG Total Score at Week 26 | Response is defined as reduction of the QMG total score by >= 5 points from baseline at Week 26 | Baseline up to Week 26 | |
| Secondary | Change From Baseline in Myasthenia Gravis Composite (MGC) Total Score at Week 26 | Baseline, Week 26 |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT05514873 -
An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Complement Component 5 Inhibitors
|
Phase 3 | |
| Completed |
NCT04124965 -
A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis
|
Phase 3 | |
| Recruiting |
NCT04833894 -
Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04963270 -
A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis
|
Phase 3 | |
| Active, not recruiting |
NCT02950155 -
A Study Evaluating the Safety and Efficacy of Rituximab in Patients With Myasthenia Gravis
|
Phase 3 | |
| Completed |
NCT03315130 -
Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis
|
Phase 2 | |
| Recruiting |
NCT06055959 -
A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis
|
Phase 2/Phase 3 | |
| Not yet recruiting |
NCT06392386 -
A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis
|
Phase 3 | |
| Not yet recruiting |
NCT06149559 -
A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis
|
Phase 2/Phase 3 | |
| Completed |
NCT03920293 -
Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis
|
Phase 3 | |
| Not yet recruiting |
NCT06193889 -
A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Subjects With Refractory Generalized Myasthenia Gravis
|
Phase 2 | |
| Completed |
NCT03770403 -
A Safety and Tolerability Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness.
|
Phase 3 | |
| Completed |
NCT03971422 -
A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis
|
Phase 3 | |
| Recruiting |
NCT05403541 -
Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis
|
Phase 3 | |
| Recruiting |
NCT05644561 -
Evaluation of Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of Ravulizumab Administered Intravenously in Pediatric Participants With Generalized Myasthenia Gravis (gMG)
|
Phase 3 | |
| Completed |
NCT00515450 -
Efficacy and Safety Study of GB-0998 for Treatment of Generalized Myasthenia Gravis
|
Phase 3 | |
| Recruiting |
NCT06064695 -
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Myasthenia Gravis
|
N/A | |
| Withdrawn |
NCT04982289 -
Study of ALXN1830 Administered Subcutaneously in Adults With Generalized Myasthenia Gravis
|
Phase 2 | |
| Completed |
NCT04735432 -
Evaluating the Pharmacodynamic Noninferiority of Efgartigimod PH20 SC Administered Subcutaneously as Compared to Efgartigimod Administered Intravenously in Patients With Generalized Myasthenia Gravis
|
Phase 3 | |
| Completed |
NCT04650854 -
A Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis
|
Phase 3 |